Copenhagen, February 24th, 2017 – MC2 Therapeutics today announced that two abstracts were accepted for poster presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Baltimore, Maryland, May 7th – 11th, 2017.
Jesper J. Lange, President of MC2 Therapeutics commented: “The real-life data we are presenting at ARVO provide further insight into the promise of PADciclo ™ as a potential treatment option for moderate-to-severe dry eye,” he added: “These detailed results, combined with pre-clinical data that will be presented at the meeting, also underscore the tremendous pwotential of our PAD ™ Technology to help addressing a wide range of unmet medical needs.”
“Retrospective evaluation of real-life efficacy of PADciclo ™ 0.06% ciclosporin in dry eye patients” will be presented by Morten Praestegaard, MC2 Therapeutics.
Session Number: 315
- Poster Number: 2662 – A0252
- Session Title: Dry eye, Clinical
- Date/Time: May 9, 2017 from 8:30 AM to 10:15 AM
“Ocular tolerability of a ciclosporin eye drop based on PAD ™ technology” will be presented by Frédéric Gomez, MC2 Therapeutics.
- Session Number: 133
- Poster Number: 484 – A0409
- Session Title: Dry eye, non-clinical
- Date/Time: May 7, 2017 from 1:30 PM to 3:15 PM
About MC2 Therapeutics
MC2 Therapeutics is a clinical stage emerging specialty pharmaceutical company focused on the development and commercialization of topical drugs in dermatology and ophthalmology. Using our new class of cream and eye drops based on our proprietary PAD ™ Technology we are developing a pipeline of new topical drugs based on the most efficacious and safe API’s designed for optimal patient compliance. We aim to provide a unique experience for patients and an attractive benefit to value proposition for payers.
MC2 Therapeutics Contact
Jesper J. Lange, President
+45 2018 2222
jjl@mc2therapeutics.com
BACK
